Head-To-Head Review: Chemours (NYSE:CC) and BioLargo (NASDAQ:BLGO)

BioLargo (NASDAQ:BLGO) and Chemours (NYSE:CC) are both construction companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Valuation & Earnings

This table compares BioLargo and Chemours”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLargo	$12.23 million	5.89	-$3.50 million	($0.03)	-8.00
Chemours	$5.74 billion	0.49	-$238.00 million	($2.17)	-8.62

BioLargo has higher earnings, but lower revenue than Chemours. Chemours is trading at a lower price-to-earnings ratio than BioLargo, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioLargo and Chemours’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLargo	-16.53%	-58.35%	-32.12%
Chemours	2.16%	33.21%	3.14%

Volatility & Risk

BioLargo has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, Chemours has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500.

Institutional & Insider Ownership

0.0% of BioLargo shares are owned by institutional investors. Comparatively, 76.3% of Chemours shares are owned by institutional investors. 20.3% of BioLargo shares are owned by company insiders. Comparatively, 0.5% of Chemours shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and target prices for BioLargo and Chemours, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLargo	0	0	0	0	N/A
Chemours	0	5	3	0	2.38

Chemours has a consensus price target of $26.75, indicating a potential upside of 43.05%. Given Chemours’ higher probable upside, analysts clearly believe Chemours is more favorable than BioLargo.

Summary

Chemours beats BioLargo on 8 of the 13 factors compared between the two stocks.

About BioLargo

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging. The Thermal & Specialized Solutions segment offers of refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents. The Advanced Performance Materials segment products portfolio includes various industrial resins, specialty products, membranes, and coatings for electronics, communications, transportation, wire and cable, energy, oil and gas, and medical, and other applications under the eflon, Viton, Krytox, and Nafion brands. The company sells its products through direct and indirect channels, as well as through a network of resellers and distributors. The Chemours Company was incorporated in 2014 and is headquartered in Wilmington, Delaware.